322 related articles for article (PubMed ID: 11782719)
1. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
[TBL] [Abstract][Full Text] [Related]
2. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
3. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
5. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience.
Dejong CH; Parks RW; Currie E; Piris J; Redhead DN; Garden OJ
J R Coll Surg Edinb; 2002 Apr; 47(2):495-9. PubMed ID: 12018694
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
9. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of endocrine gastroenteropancreatic tumors.
Tomassetti P; Campana D; Nori F; Piscitelli L; Salomone L; Pezzilli R; Corinaldesi R
JOP; 2006 Jan; 7(1):145-9. PubMed ID: 16407637
[No Abstract] [Full Text] [Related]
11. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
12. [State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies].
Guida T; Belsito Petrizzi V; Fiorentino R; Germano D; Guardasi R; Lentini-Graziano ML; Cartenì G
Minerva Endocrinol; 2001 Dec; 26(4):215-24. PubMed ID: 11782706
[TBL] [Abstract][Full Text] [Related]
13. Cases in the Management of NETs: Focus on Sequencing Somatostatin Analogs.
Iyer R
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):4-7. PubMed ID: 27167991
[No Abstract] [Full Text] [Related]
14. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
15. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
Filosso PL; Ruffini E; Oliaro A; Rena O; Casadio C; Mancuso M; Turello D; Cristofori RC; Maggi G
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):819-24. PubMed ID: 15821649
[TBL] [Abstract][Full Text] [Related]
16. Established clinical use of octreotide and lanreotide in oncology.
Oberg K
Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
[TBL] [Abstract][Full Text] [Related]
17. [Merkel cell tumor. Report of case and treatment with octreotide].
Cirillo F; Filippini L; Lima GF; Caresana G; Alquati P
Minerva Chir; 1997 Nov; 52(11):1359-65. PubMed ID: 9489335
[TBL] [Abstract][Full Text] [Related]
18. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L; Vinik AI
Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
